Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Gross Profit (2019 - 2025)

Akebia Therapeutics (AKBA) has disclosed Gross Profit for 7 consecutive years, with $45.1 million as the latest value for Q4 2025.

  • Quarterly Gross Profit fell 27.48% to $45.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $196.7 million through Dec 2025, up 30.23% year-over-year, with the annual reading at $196.7 million for FY2025, 47.87% up from the prior year.
  • Gross Profit for Q4 2025 was $45.1 million at Akebia Therapeutics, down from $49.4 million in the prior quarter.
  • The five-year high for Gross Profit was $62.2 million in Q4 2024, with the low at -$20.6 million in Q4 2022.
  • Average Gross Profit over 5 years is $26.2 million, with a median of $28.8 million recorded in 2023.
  • The sharpest move saw Gross Profit tumbled 2299.76% in 2022, then skyrocketed 623.14% in 2023.
  • Over 5 years, Gross Profit stood at -$10.4 million in 2021, then crashed by 98.39% to -$20.6 million in 2022, then skyrocketed by 216.67% to $24.0 million in 2023, then surged by 158.66% to $62.2 million in 2024, then decreased by 27.48% to $45.1 million in 2025.
  • According to Business Quant data, Gross Profit over the past three periods came in at $45.1 million, $49.4 million, and $52.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.